An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

PHASE3CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Generalized Myasthenia Gravis
Interventions
BIOLOGICAL

ARGX-113

Intravenous administration of ARGX-113

BIOLOGICAL

Placebo

Intravenous administration of placebo

Trial Locations (66)

1204

Investigator Site 55, Budapest

2100

Investigator Site 15, Copenhagen

2650

Investigator Site 11, Edegem

6725

Investigator Site 54, Szeged

8200

Investigator Site 36, Aarhus

9000

Investigator Site 8, Ghent

10117

Investigator Site 33, Berlin

11000

Investigator Site 61, Belgrade

13385

Investigator Site 52, Marseille

14202

Investigator Site 53, Buffalo

20133

Investigator Site 10, Milan

22908

Investigator Site 2, Charlottesville

27599

Investigator Site 3, Chapel Hill

29425

Investigator Site 17, Charleston

32209

Investigator Site 34, Jacksonville

33076

Investigator Site 13, Bordeaux

33612

Investigator Site 4, Tampa

38018

Investigator Site, Cordova

44195

Investigator Site 20, Cleveland

48201

Investigator Site 48, Detroit

52242

Investigator Site 25, Iowa City

62500

Investigator Site 32, Brno

62702

Investigator Site 30, Springfield

66160

Investigator Site 21, Kansas City

70852

Investigator Site 35, Ostrava-Poruba

77030

Investigator Site 44, Houston

78229

Investigator Site 6, San Antonio

80045

Investigator Site 58, Aurora

80131

Investigator Site 12, Napoli

85018

Investigator Site 29, Phoenix

90033

Investigator Site 5, Los Angeles

90095

Investigator Site 49, Los Angeles

92011

Investigator Site 66, Carlsbad

92868

Investigator Site 18, Orange

94115

Investigator Site 59, San Francisco

94304

Investigator Site 40, Palo Alto

97239

Investigator Site 9, Portland

98195

Investigator Site 16, Seattle

443095

Investigator Site 60, Samara

603126

Investigator Site 62, Nizhny Novgorod

630087

Investigator Site 65, Novosibirsk

660037

Investigator Site 64, Krasnoyarsk

1538515

Investigator Site 31, Meguro City

5898511

Investigator Site 28, Ōsaka-sayama

02115

Investigator Site 27, Boston

T6G 2G3

Investigator Site 38, Edmonton

M5G 2C4

Investigator Site 24, Toronto

H3A 2B4

Investigator Site 22, Montreal

128 00

Investigator Site 51, Prague

0112

Investigator Site 46, Tbilisi

0114

Investigator Site 45, Tbilisi

Investigator Site 47, Tbilisi

260-8677

Investigator Site 42, Chiba

0608543

Investigator Site 26, Sapporo

025-0075

Investigator Site 19, Hanamaki

983-8520

Investigator Site 43, Sendai

565-0871

Investigator Site 50, Suita

108-8329

Investigator Site 41, Minato-Ku

160-0023

Investigator Site 39, Shinjuku-Ku

2333 ZA

Investigator Site 37, Leiden

80-952

Investigator Site 7, Gdansk

40-123

Investigator Site 57, Katowice

31-505

Investigator Site 14, Krakow

02-097

Investigator Site 23, Warsaw

B15 2TH

Investigator Site 63, Edgbaston

L9 7LJ

Investigator Site 56, Liverpool

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY